Published date: Mar 14 2024

Journal Title: West Kazakhstan Medical Journal

Issue title: West Kazakhstan Medical Journal: Volume 66 Issue 1

Pages: 94–105

DOI: 10.18502/wkmj.v66i1.15682

Zhenisgul Sh. Tlegenova

Saule K. Balmagambetova - sau3567@gmail.com - https://orcid.org/0000-0003-4080-5383

Bekolat K. Zholdin

Gulnara L. Kurmanalina

Iliada Zh. Talipova

Arip K. Koyshybaev

Gulmira A. Sultanbekova

Kulparshan I. Kubenova

Mira B. Baspayeva

Saule S. Madinova

Ayganym Amanova

In Kazakhstan, breast cancer (BC) remains the leading cause of cancer morbidity and mortality among women. The presented case series aims to summarize cardiovascular events that resulted in anthracycline-based chemotherapy discontinuation or suspension during the ongoing project on studying the cardiotoxicity effects. Case 1. Classic acute cardiotoxicity with asystole. Patient Sh., 46 years old, was admitted with a baseline LVEF of 64% and GLS of 22.4%. After the first dose of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, the patient experienced two episodes of asystole. She was prescribed Trimetazidine at a dose of 80 mg. Eventually, Sh. completed the courses of anthracycline therapy after a 1-month delay at a cumulative dose of 455 mg/m2. Case 2. Subacute cardiotoxicity with ventricular extrasystole. Patient Zh., aged 47, developed single, paired, and group ventricular extrasystoles after the 2nd course of chemotherapy with doxorubicin 200 mg/m2 (23 days after admission). Carvedilol was prescribed at 25 mg twice daily and Trimetazidine at 80 mg once a day. After 1 month of monitoring, ventricular extrasystoles disappeared. With a month’s delay, the patient completed chemotherapy at a cumulative dose of 400 mg/m2. Case 3. Severe cardiotoxicity due to pre-existing cardiovascular disease with discontinuation of chemotherapy. Patient M., aged 58, was referred to the very highrisk group for developed atrial fibrillation and heart failure with LVEF 51%. M. received Enalapril 5 mg two times per day, Bisoprolol 5 mg, Eplerenone 50 mg, Dapagliflozin 10 mg, and Dabigatran 150 mg twice daily. After 3 months, anthracycline therapy was canceled at a cumulative dose of 260 mg/m2 due to the deterioration of the patient’s condition (LVEF 41%.). Discontinuation or the delay of vitally needed chemotherapy in BC patients deteriorate their prognosis for survival. Patients should be constantly monitored during and after anticancer treatment.

[1] Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022 Dec;66:15–23.

[2] The Global Cancer Observatory. Kazakhstan. Available online: [https://gco.iarc.fr/today/data/factsheets/populations/398-kazakhstan-factsheets. pdf] (accessed on 10 March 2021)

[3] Midlenko A, Mussina K, Zhakhina G, Sakko Y, Rashidova G, Saktashev B, et al. Prevalence, incidence, and mortality rates of breast cancer in Kazakhstan: Data from the Unified National Electronic Health System, 2014-2019. Front Public Health. 2023 Apr;11:1132742.

[4] Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022 Sep;72(5):409– 436.

[5] Berry LL, Davis SW, Godfrey Flynn A, Landercasper J, Deming KA. Is it time to reconsider the term “cancer survivor”? J Psychosoc Oncol. 2019;37(4):413–426.

[6] Abdel-Qadir H, Austin P, Lee D, Amir E, Tu J, Thavendiranathan P, et al. A population-based study of cardiovascular mortality following early-stage breast cancer. JAMA Cardiology. 2017;2(1):88–93. cardiology. https://doi.org/10.1001/jamacardio.2016.3841.

[7] Wang C, He T, Wang Z, Zheng D, Shen Z. Relative risk of cardiovascular mortality in breast cancer patients: A population-based study. Rev Cardiovasc Med. 2022;23(4):120.

[8] Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: An international cardio-oncology society (IC-OS) consensus statement. Eur Heart J. 2022 Jan;43(4):280–299.

[9] Ades F, Zardavas D, Pinto AC, Criscitiello C, Aftimos P, de Azambuja E. Cardiotoxicity of systemic agents used in breast cancer. Breast. 2014 Aug;23(4):317–328.

[10] Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015 Jun;131(22):1981–1988.

[11] Christidi E, Brunham LR. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death Dis. 2021 Apr;12(4):339.

[12] Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity. J Clin Oncol. 2005 May;23(13):2900–2902.

[13] Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer. 2003 Jun;97(11):2869– 2879.

[14] Briasoulis A, Chasouraki A, Sianis A, Panagiotou N, Kourek C, Ntalianis A, et al. Cardiotoxicity of non-anthracycline cancer chemotherapy agents. J Cardiovasc Dev Dis. 2022 Feb;9(3):66.

[15] Ben Kridis W, Sghaier S, Charfeddine S, Toumi N, Daoud J, Kammoun S, et al. A prospective study about Trastuzumab-induced cardiotoxicity in HER2-positive breast cancer. Am J Clin Oncol. 2020 Jul;43(7):510–516.

[16] Ganesh S, Zhong P, Zhou X. Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment. Front Cardiovasc Med. 2022 Sep;9:997660.

[17] Alkofide H, Alnaim L, Alorf N, Alessa W, Bawazeer G. Cardiotoxicity and cardiac monitoring among anthracycline-treated cancer patients: A retrospective cohort study. Cancer Manag Res. 2021 Jun;13:5149–5159.

[18] Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2017 Mar;35(8):893–911.

[19] Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019 Dec;40(48):3889–3897.

[20] Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al.; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and theInternational Cardio-Oncology Society (IC-OS). Eur Heart J. 2022 Nov;43(41):4229– 4361.

[21] Genuino AJ, Chaikledkaew U, The DO, Reungwetwattana T, Thakkinstian A. Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: A systematic review and meta-analysis. Expert Rev Clin Pharmacol. 2019 Aug;12(8):815–824.

[22] Fujii T, Le Du F, Xiao L, Kogawa T, Barcenas CH, Alvarez RH, et al. Effectiveness of an adjuvant chemotherapy regimen for early-stage breast cancer: A systematic review and network meta-analysis. JAMA Oncol. 2015 Dec;1(9):1311–1318.

[23] Vasyuk Y, Gendlin G, Emelina E, Shupenina E, Ballyuzek M, Barinova I, et al. Consensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy [in Russian]. Russ J Cardiol. 2021;26(9):4703.

[24] Tlegenova Z, Balmagambetova S, Zholdin B, Kurmanalina G, Talipova I, Koyshybaev A, et al. Stratifying breast cancer patients by baseline risk of cardiotoxic complications linked to chemotherapy. J Clin Med Kaz. 2023;20(3):75-81. 10.23950/jcmk/13325.